Sermorelin research: pituitary responses in people

Sermorelin mechanism of action

Sermorelin acts at the GHRH receptor on growth-hormone-producing pituitary cells. Receptor activation sets off cAMP and protein kinase A signalling inside the cell, increasing growth hormone synthesis and release. The review of GHRH and its analogues places this machinery in the wider hormone system.

Growth hormone stimulates liver production of IGF-1, while IGF-1 and somatostatin provide feedback that can restrain release. An editorial favoured this feedback-regulated approach to adult growth hormone insufficiency over supplying growth hormone directly. I appreciate the responsive-gland rationale. Establishing a clinical advantage still requires a comparison of outcomes.

Childhood height growth and diagnostic testing

In the multicenter trial of prepubertal growth-hormone-deficient children, first-year growth increased from about 4.1 to roughly 7-8 centimeters per year. IGF-1 generation stayed below excessive levels. A measured growth improvement beside a relevant biological response gives the childhood record substance. I respect that pairing.

Stimulation tests asked a different question: how much hormone could the pituitary release when prompted? Children with growth hormone deficiency had a reduced response compared with normal-stature children, with a partial response in some suggesting a hypothalamic origin. Another comparison of GHRH and GHRP-2 separated blunted responses in GH insufficiency from larger responses in idiopathic short stature. The diagnosis affected the reply.

The dosage page puts the historical study amounts alongside these purposes.

Older men’s GH and IGF-1 results

The 14-day study in older men found dose-related increases in 24-hour GH and IGF-1. At the higher study amount, these measures no longer differed from those in younger men. Fasting glucose stayed unchanged.

The appeal of that blood result is easy to understand. It compresses an attractive idea about aging into a blood result. The study establishes hormone responsiveness over its observation period; sustained improvements in strength, function and health remain open questions. The skeptical aging editorial is a useful companion to the result.

Continuous infusion

Here the apparently obvious improvement—make the supply continuous—ran into trouble. In six children with partial GH deficiency, continuous subcutaneous GHRH(1-29) infusion produced an early increase in integrated GH, followed by a consistent decline by 3 to 6 months. One child showed complete suppression of GH secretion.

The investigators considered antibodies, changes in somatostatin and reduced sensitivity of pituitary receptors as possible explanations. The study leaves the mechanism unsettled. It does establish the fading response in that small group under that delivery method.

This experiment overturned my expectation that a steadier supply would give a steadier useful response. I now regard the pattern of stimulation as a serious biological question. It gives no basis for choosing a personal injection schedule.

Sermorelin vs tesamorelin: cognition and body fat

The controlled trial in 152 older adults, including 66 with mild cognitive impairment used tesamorelin, a stabilized GHRH analogue. Over 20 weeks, treatment improved thinking-task performance, increased IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4%. Reported adverse events were mild.

I credit that trial with testing something people care about beyond a hormone measurement. Its drug name matters just as much as its outcome. These results establish findings for tesamorelin in that trial; sermorelin needs direct evidence for the same claims.

Sermorelin weight loss

The 16-week [study of the modified analogue [Nle27]GHRH-(1-29)-NH2](https://pubmed.ncbi.nlm.nih.gov/9141536/) found no change in body weight. That preparation substitutes a part of the peptide and must be identified separately from ordinary sermorelin.

The supplied evidence leaves comparable weight-loss and muscle gains in healthy adults receiving sermorelin unestablished. Growth hormone’s role in using fat for fuel helps explain the research interest, while changes in body weight, muscle size and strength each require their own measurements. The community reports describe how easily those outcomes become tangled together.

Sermorelin vs ipamorelin

Sermorelin stimulates the GHRH receptor. Ipamorelin uses the separate ghrelin/GHS receptor, normally responsive to a hormone involved in hunger. The mechanism record distinguishes these receiving points, within the broader physiology of growth hormone release.

Combining stimuli is a research rationale because their effects on hormone release can add up. The implied health advantage of pairing those stimuli remains unconvincing to me when that rationale is the only support.

Nighttime sampling and sleep

Growth hormone is released in pulses, especially during deep sleep. The nightly GHRH(1-29) study in healthy elderly men examined the GH/IGF-1 axis and whether nighttime output could be restored.

That protocol helps explain the focus on bedtime in this literature. Its measured question was hormone output. The vivid-dream and restful-sleep accounts on the effects page are anecdotal accounts, not clinical evidence of a sleep benefit from sermorelin.

Experimental heart research

An animal cardiac study of GHRH-receptor targeting reported improved post-infarction cardiac outcomes with an experimental agonist. This was preclinical work with a related experimental medicine. It provides a lead for cardiac research, while human sermorelin heart treatment remains unestablished.

The GHRH review ranges across agonists, which activate the receptor, and antagonists, which block it. That breadth is interesting in its own right. Compressing those different compounds and purposes into a list of sermorelin benefits strikes me as careless.